JP3746986B2 - Whitening agent and skin external preparation for whitening - Google Patents
Whitening agent and skin external preparation for whitening Download PDFInfo
- Publication number
- JP3746986B2 JP3746986B2 JP2001351904A JP2001351904A JP3746986B2 JP 3746986 B2 JP3746986 B2 JP 3746986B2 JP 2001351904 A JP2001351904 A JP 2001351904A JP 2001351904 A JP2001351904 A JP 2001351904A JP 3746986 B2 JP3746986 B2 JP 3746986B2
- Authority
- JP
- Japan
- Prior art keywords
- whitening
- tyrosinase
- mifepristone
- skin external
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002087 whitening effect Effects 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 12
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 21
- 229960003248 mifepristone Drugs 0.000 claims description 20
- 102000003425 Tyrosinase Human genes 0.000 description 38
- 108060008724 Tyrosinase Proteins 0.000 description 38
- 230000000694 effects Effects 0.000 description 22
- 210000002752 melanocyte Anatomy 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- -1 steroid compounds Chemical class 0.000 description 11
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 230000008099 melanin synthesis Effects 0.000 description 8
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 6
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- 239000007844 bleaching agent Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- 235000011076 sorbitan monostearate Nutrition 0.000 description 4
- 239000001587 sorbitan monostearate Substances 0.000 description 4
- 229940035048 sorbitan monostearate Drugs 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 229940123788 Progesterone receptor antagonist Drugs 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は美白剤および美白用皮膚外用剤に関し、特にヒトメラノサイト内における酵素チロシナーゼに作用し、その量を減少させる美白剤およびその美白剤を用いた美白用皮膚外用剤に関する。
【０００２】
【従来の技術】
皮膚のしみ、そばかすなどの色素沈着は、ホルモンの異常や紫外線の刺激がきっかけとなって表皮メラノサイト内のメラニン色素の産生が過剰になり発生する。
従来、しみ、そばかすを防止するためにメラニン色素の生成を抑制する物質について研究され、メラニン色素の生成過程の生化学反応の第一段階を触媒する酵素チロシナーゼの活性を阻害する物質、例えばハイドロキノン、コウジ酸、あるいは酸化によるメラニン色素の黒化過程を抑えるアスコルビン酸、システインなどが美白剤として知られている。また、アルブチンは酵素チロシナーゼの活性阻害またはメラニン生合成阻害作用があり、代表的な美白剤として知られている。これら美白剤を軟膏、クリーム、ローションなどの皮膚外用剤に配合して美白用皮膚外用剤が得られ、局所に塗布するなどの方法がとられている。
【０００３】
【発明が解決しようとする課題】
しかしながら、これらのものの多くは、安定性、安全性、匂い等の面において問題があり、また、期待できる効果は弱く、未だ満足のいくものではなかった。本発明は、このような問題に対処するためになされたもので、安定性、安全性に優れるとともに、優れた美白効果を発揮する美白剤およびその美白剤を用いた美白用皮膚外用剤の提供を目的とする。
【０００４】
【課題を解決するための手段】
本発明に係る美白剤は、ミフェプリストンを含むことを特徴とする。
【０００５】
本発明に係る美白用皮膚外用剤は、メラノサイト内の酵素チロシナーゼ量を減少させる物質、特にミフェプリストンを含むことを特徴とする。
【０００６】
表皮メラノサイト内のメラニン色素合成を促進する酵素チロシナーゼ産生は次のように考えられている。
（１）紫外線など外部からメラノサイトを刺激したり、ホルモンの異常が発生したりする。
（２）酵素チロシナーゼ（チロシナーゼタンパク）合成の設計図を細胞核内のＤＮＡからチロシナーゼｍＲＮＡに転写し、細胞質に伝達する。
（３）酵素チロシナーゼを産生する。
【０００７】
メラノサイト内でメラニン色素合成の中心的な役割を果たしているのが酵素チロシナーゼである。従来、この酵素に対して直接作用して酵素活性を阻害する成分、例えばコウジ酸などの探索が行なわれ、美白剤として使用されている。
本願発明者は、上記方法とは異なる方法、すなわち、メラノサイト内の酵素チロシナーゼに直接作用して酵素活性を阻害することはないが、その量を減少させることにより、メラニン色素合成量を抑えることができることを見出した。
上述した酵素チロシナーゼ産生機序を考えると、メラノサイト内の酵素チロシナーゼ量の減少は、チロシナーゼｍＲＮＡの転写を抑制しているか、あるいは、酵素チロシナーゼが作られても安定性が悪くすぐに分解されるのではないかと考えられる。酵素チロシナーゼはタンパク質であるので、通常でも分解は常に起こっているが、その分解スピードが速くなっていると考えられる。
【０００８】
他の美白剤として、細胞を白くする成分の探索も行なわれてきた。しかしながらその使用されてきた細胞は人の正常なメラノサイトではなく、マウスのメラノーマ（メラノサイトがガン化したもの）が中心であったため、細胞に対する毒性作用でも白くなる、ＰＨの変動でも白くなるなど、簡単には白くならない人の正常なメラノサイトに対して真の美白化作用を持つ物質の探索は困難であった。
本発明に係る、ヒトメラノサイト内の酵素チロシナーゼ量を減少させる物質を配合した美白剤は、酵素チロシナーゼ量自身を減少させるので、人の正常メラノサイトに対して効果を示す。
【０００９】
【発明の実施の形態】
ヒトメラノサイト内の酵素チロシナーゼ量を減少させる物質は、ヒトメラノサイトに作用して、酵素チロシナーゼの産生を抑制する物質であっても、あるいは酵素チロシナーゼを速やかに分解させる物質であってもよい。例えば、酵素チロシナーゼの産生を抑制する物質としては、チロシナーゼｍＲＮＡの転写を抑制できる物質が挙げられる。
また、プロゲステロン／糖質コルチコイドレセプターに結合してアゴニストの効果を阻害するが、それ自体はレセプターと結合しても効果を発揮できない物質で、拮抗薬、遮断薬とも称されるアンタゴニストが酵素チロシナーゼ量を減少させる物質として挙げられる。
【００１０】
ヒトメラノサイトに作用して細胞内チロシナーゼ活性を減少させる効果を有する物質として、プロゲステロン／糖質コルチコイドレセプターアンタゴニスト活性を有するステロイド化合物が挙げられる。その構造は上記式（Ｉ）で表される。なお、Ｒ1において、３〜６個の炭素原子を含有するシクロアルキル基またはフェニル基の誘導体としては、ヒドロキシ、ハロゲン、トリフルオルメチル基、炭素数６以下のアルキル、アルコキシ、スルホキシドまたはスルホンの形で酸化あるいは非酸化されているアルキルチオ基が挙げられる。
また、Ｒ4において、アルケニル若しくはアルキニル基の誘導体としては、アミノ、アルキルアミノ、ジアルキルアミノ、ハロゲン、アルキルチオ、アルコキシ、トリアルキルシリル若しくはシアノ基により置換されている基をそれぞれ示す。
また、ＡおよびＢについては、Ｒ4がアミノ官能基を含有する基を表わすときは、製薬または美白用皮膚外用剤上許容できる酸との付加塩を含むものとする。
【００１１】
酵素チロシナーゼ量を減少させる具体的な物質を例示すれば、ミフェプリストンが挙げられる。
ミフェプリストンは、１７β−ヒドロキシ−１１β−（４−ジメチルアミノフェニル）−１７α−（１−プロピニル）エストラ−４，９−ジエン−３−オンで、ＲＵ４８６とも称され、以下に示す式（ＩＩ）で表される合成ステロイドの１種である。
【化３】
ミフェプリストンの作用について、（１）細胞内チロシナーゼ活性の測定、（２）細胞数の測定（ＭＴＴ活性）を行ない評価した。測定方法を以下に示す。
（１）細胞内チロシナーゼ活性の測定方法
正常ヒト表皮メラニン細胞（クラボウ）を２４ウェルプレートに２万個／ウェルとなるように分植し、４８時間後に培地をＭＣＤＢ１５３＋５％ＦＢＳ＋４ｎＭ ＰＭＡに交換し、さらに４８時間後に各種試験検体を含む同様の培地を作用した。
【００１３】
試験検体は、ミフェプリストン２０μＭ、フォルスコリン１０μＭ、ミフェプリストン２０μＭ＋フォルスコリン１０μＭを用いる検体と、ミフェプリストン２０μＭ、α−ＭＳＨ（メラノサイト刺激ホルモン）５００ｎＭ、ミフェプリストン２０μＭ＋α−ＭＳＨ５００ｎＭを用いる検体とをそれぞれ準備した。
フォルスコリンはメラニン合成を活発にする細胞内セカンドメッセンジャーとして知られるｃＡＭＰを、アデニル酸シクラーゼを刺激することでその量を増やす物質として研究に頻用されているため、また、α−ＭＳＨはケラチノサイトあるいはメラノサイト自身から放出され、パラクラインあるいはオートクラインにメラニン合成を活発にすることが知られているため、フォルスコリンまたはα−ＭＳＨによる細胞内チロシナーゼ活性の増大をミフェプリストンがどの程度抑制できるかを調査するために用いた。
【００１４】
４８時間後に培地を除去し、１％ＴｒｉｔｏｎＸ−１００を含む１００ｍＭリン酸緩衝液（ｐＨ６．８）０．１ｍｌを添加後、軽く超音波処理し、０．１％Ｄｏｐａを含む５０ｍＭリン酸緩衝液（ｐＨ６．８）０．２ｍｌを添加し、３７℃、３時間反応し、４５０ｎｍの吸光度を測定した。市販のマッシュルーム由来チロシナーゼをスタンダードとして作成した検量線からウェルあたりのチロシナーゼ量を算出し、コントロールとの相対値として表わした。結果を表１に示す。
【００１５】
（２）細胞数の測定（ＭＴＴ活性）方法
上記細胞内チロシナーゼ活性の測定方法と同様にして各種試験検体を作用して４８時間後に培地を除去し、０．０５％ＭＴＴ：臭化３−（４，５−ジメチル−２−チアゾリル）−２，５−ジフェニル−２Ｈ−テトラゾリウムを含むＭＣＤＢ１５３＋５％ＦＢＳ＋４ｎＭ ＰＭＡ０．３ｍｌに交換し、さらに４時間３７℃で培養した。０．０４ＮＨＣＩを含むイソプロピルアルコール０．３ｍｌを添加し、不溶物を溶解し、６５５ｎｍをリファレンスとして５４０ｎｍの吸光度を測定した。あらかじめ作成した細胞数と吸光度の検量線から細胞数を算出し、コントロールとの相対値として表わした。結果を表１に示す。
【００１６】
【表１】
また、代表的な美白剤であるアルブチンを比較例に用いて上記と同様な方法で細胞内チロシナーゼ活性およびＭＴＴ活性の測定を行なった。結果を表２に示す。
【００１８】
【表２】
表１により、ミフェプリストンはフォルスコリンやα−ＭＳＨによる細胞数の上昇にも僅かに影響を与えるものの、細胞内チロシナーゼ活性の上昇に与える影響がはるかに大きいことが分かる。
また、表２に示すアルブチンとの比較により、ミフェプリストンの細胞内チロシナーゼ活性を下げる作用は、すでに美白剤として使われているアルブチンを１０倍濃度の２００ｍＭで作用するよりも強い。したがって、ミフェプリストンは優れたメラニン生成抑制効果を有する。
【００２０】
本発明の美白用皮膚外用剤は、メラノサイト内の酵素チロシナーゼ量を減少させる物質を必須成分として含んでいればよい。特にミフェプリストンを含んでいることが好ましい。
配合量は、有効成分を０．００５〜２重量％含有することが好ましい。０．００５重量％未満では美白効果がなく、２重量％をこえると美白効果の向上が望めなくなる。
【００２１】
なお、酵素チロシナーゼ量を減少させる物質の他に、他の化粧品原料、例えばコウジ酸、アスコルビン酸、ハイドロキノン、チオール系化合物等の美白剤、スクワラン、ホホバ油等の液状油、ミツロウ、セチルアルコール等の固体油、各種の活性剤、グリセリン、1,3-ブチレングリコール等の保湿剤や各種薬剤等とを添加してさまざまな剤形の美白用皮膚外用剤に調整できる。例えばローション、クリーム、乳液、パック等の目的に応じた利用形態で使用できる。
【００２２】
【実施例】
実施例１
ローションの例について説明する。配合成分と配合量（重量％）を以下に示す。
オリーブ油 ０．５
ミフェプリストン ０．５
ポリオキシエチレン（ 20 E.0 ）ソルビタンモノステアレート ２．０
ポリオキシエチレン（ 60 E.0 ）硬化ヒマシ油 ２．０
エタノール １０．０
ヒアルロン酸ナトリウム水溶液（ 1.0重量％） ５．０
精製水 ８０．０
【００２３】
精製水におよびヒアルロン酸ナトリウム水溶液加え 70 ℃に加熱調整する。オリーブ油にポリオキシエチレン（ 20 E.0 ）ソルビタンモノステアレートおよびポリオキシエチレン（ 60 E.0 ）硬化ヒマシ油を加え 70 ℃に加熱調整する。この油相を先に調整した水相に加え予備乳化し、さらにミフェプリストンおよびエタノールを加えてホモミキサーにて乳化粒子を均一にした後、脱気、濾過、冷却して実施例１のローションを得た。
【００２４】
実施例２クリームの例について説明する。配合成分と配合量（重量％）を以下に示す。
Ａ成分：
スクワラン ２０．０
オリーブ油 ２．０
ミンク油 １．０
ホホバ油 ５．０
ミツロウ ５．０
セトステアリルアルコール ２．０
グリセリンモノステアレート １．０
ソルビタンモノステアレート ２．０
Ｂ成分：
精製水 ４７．９
ポリオキシエチレン（ 20 E.0 ）ソルビタンモノステアレート ２．Ｏ
ポリオキシエチレン（ 60 E.0 ）硬化ヒマシ油 １．０
グリセリン ５．０
ミフェプリストン ０．５
ヒアルロン酸ナトリウム水溶液（ 1.0重量％） ５．０
パラオキシ安息香酸メチル ０．１
【００２５】
Ａ成分とＢ成分とをそれぞれ計量し、それぞれ 70 ℃まで加温し、Ｂ成分にＡ成分を攪拌しつつ徐々に加えたのち、ゆっくり攪拌しつつ 30 ℃まで冷却して実施例２のクリームを得た。
【００２６】
実施例１および実施例２で得られた化粧品は、使用テストの結果、ミフェプリストンを除き、水に代えた比較例に比較して、美白効果が見られた。
【００２７】
【発明の効果】
本発明は、メラノサイト内の酵素チロシナーゼ量を減少させる物質を含むので、メラニン産生を抑制できる。
また、該物質が上述したステロイド化合物であるので、特にミフェプリストンであるので、メラニン産生をより抑制できる。
メラニン産生を抑制できるので、優れた美白効果を有する美白用皮膚外用剤が得られる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a whitening agent and a whitening skin external preparation, and more particularly to a whitening agent that acts on and reduces the amount of the enzyme tyrosinase in human melanocytes and a whitening skin external preparation using the whitening agent.
[0002]
[Prior art]
Skin pigmentation, freckles, and other pigmentation occur due to excessive production of melanin pigment in epidermal melanocytes, triggered by hormonal abnormalities or stimulation of ultraviolet rays.
Conventionally, substances that suppress the formation of melanin pigments to prevent spots and freckles have been studied, and substances that inhibit the activity of the enzyme tyrosinase that catalyzes the first step of the biochemical reaction of the melanin pigment formation process, such as hydroquinone, Known as whitening agents are kojic acid, or ascorbic acid or cysteine which suppresses the darkening process of melanin pigments due to oxidation. Arbutin has an activity of inhibiting the activity of the enzyme tyrosinase or an inhibitory effect on melanin biosynthesis, and is known as a typical whitening agent. These whitening agents are blended with skin external preparations such as ointments, creams, lotions and the like to obtain skin external preparations for whitening, and are applied to the topic.
[0003]
[Problems to be solved by the invention]
However, many of these have problems in terms of stability, safety, odor and the like, and the expected effects are weak and still not satisfactory. The present invention has been made to address such problems, and provides a whitening agent that exhibits excellent whitening effects while being excellent in stability and safety, and a whitening skin external preparation using the whitening agent. With the goal.
[0004]
[Means for Solving the Problems]
The whitening agent according to the present invention includes mifepristone.
[0005]
The skin whitening preparation for whitening according to the present invention contains a substance that decreases the amount of enzyme tyrosinase in melanocytes, particularly mifepristone.
[0006]
Production of the enzyme tyrosinase that promotes melanin pigment synthesis in epidermal melanocytes is considered as follows.
(1) Stimulate melanocytes from the outside such as ultraviolet rays, or cause hormonal abnormalities.
(2) A blueprint for synthesis of the enzyme tyrosinase (tyrosinase protein) is transcribed from DNA in the cell nucleus to tyrosinase mRNA and transmitted to the cytoplasm.
(3) Produces the enzyme tyrosinase.
[0007]
The enzyme tyrosinase plays a central role in melanin synthesis in melanocytes. Conventionally, a component that acts directly on this enzyme to inhibit the enzyme activity, such as kojic acid, has been searched and used as a whitening agent.
The present inventor does not inhibit the enzyme activity by directly acting on the enzyme tyrosinase in the melanocyte, but the amount of melanin pigment synthesis can be suppressed by decreasing the amount. I found out that I can do it.
Considering the mechanism of enzyme tyrosinase production described above, the decrease in the amount of enzyme tyrosinase in melanocytes suppresses transcription of tyrosinase mRNA, or even if the enzyme tyrosinase is made, it is not stable and is readily degraded. It is thought that. Since the enzyme tyrosinase is a protein, degradation always occurs normally, but it is thought that the degradation speed is increased.
[0008]
Other whitening agents have also been searched for components that whiten cells. However, since the cells that have been used are not normal human melanocytes but mainly mouse melanomas (the melanocytes are cancerous), they become white due to toxic effects on cells, and white due to fluctuations in pH. It was difficult to search for substances that have a real whitening effect on normal melanocytes of people who do not turn white.
The whitening agent containing the substance for reducing the amount of enzyme tyrosinase in human melanocytes according to the present invention reduces the amount of enzyme tyrosinase itself, and thus has an effect on human normal melanocytes.
[0009]
DETAILED DESCRIPTION OF THE INVENTION
The substance that reduces the amount of the enzyme tyrosinase in human melanocytes may be a substance that acts on human melanocytes to suppress the production of the enzyme tyrosinase, or a substance that rapidly degrades the enzyme tyrosinase. For example, the substance that suppresses the production of the enzyme tyrosinase includes a substance that can suppress the transcription of tyrosinase mRNA.
In addition, it binds to the progesterone / glucocorticoid receptor and inhibits the effect of the agonist, but itself does not exert the effect even when bound to the receptor. The antagonist, also called antagonist or blocker, is an enzyme tyrosinase level. As a substance that reduces
[0010]
Examples of substances having an effect of acting on human melanocytes to reduce intracellular tyrosinase activity include steroid compounds having progesterone / glucocorticoid receptor antagonist activity. Its structure is represented by the above formula (I). In R 1 , the derivative of a cycloalkyl group or a phenyl group containing 3 to 6 carbon atoms includes hydroxy, halogen, trifluoromethyl group, alkyl having 6 or less carbon atoms, alkoxy, sulfoxide or sulfone. And alkylthio groups that are oxidized or non-oxidized.
In R 4 , an alkenyl or alkynyl group derivative represents an amino, alkylamino, dialkylamino, halogen, alkylthio, alkoxy, trialkylsilyl, or a group substituted by a cyano group.
As for A and B, when R 4 represents a group containing an amino functional group, it includes an addition salt with an acid that is acceptable on a pharmaceutical or whitening skin external preparation.
[0011]
An example of a specific substance that reduces the amount of the enzyme tyrosinase is mifepristone.
Mifepristone is 17β-hydroxy-11β- (4-dimethylaminophenyl) -17α- (1-propynyl) estradi-4,9-dien-3-one, also referred to as RU486, and has the formula (II ).
[Chemical 3]
The action of mifepristone was evaluated by (1) measuring intracellular tyrosinase activity and (2) measuring the number of cells (MTT activity). The measuring method is shown below.
(1) Method for measuring intracellular tyrosinase activity Normal human epidermal melanocytes (Kurabo) are planted in a 24-well plate at 20,000 cells / well, and after 48 hours, the medium is replaced with MCDB153 + 5% FBS + 4 nM PMA. 48 hours later, the same medium containing various test specimens was acted.
[0013]
The test sample is a sample using mifepristone 20 μM, forskolin 10 μM, mifepristone 20 μM + forskolin 10 μM, a sample using mifepristone 20 μM, α-MSH (melanocyte stimulating hormone) 500 nM, mifepristone 20 μM + α-MSH 500 nM, Prepared each.
Forskolin is frequently used in research as a substance that increases the amount of cAMP known as an intracellular second messenger that activates melanin synthesis by stimulating adenylate cyclase, and α-MSH is also used for keratinocytes or melanocytes. Investigate how much mifepristone can suppress the increase of intracellular tyrosinase activity by forskolin or α-MSH because it is released from itself and is known to activate melanin synthesis in paracrine or autocrine Used to do.
[0014]
After 48 hours, the medium was removed and 0.1 ml of 100 mM phosphate buffer (pH 6.8) containing 1% Triton X-100 was added, followed by light sonication and 50 mM phosphate buffer containing 0.1% Dopa. (PH 6.8) 0.2 ml was added, reacted at 37 ° C. for 3 hours, and absorbance at 450 nm was measured. The amount of tyrosinase per well was calculated from a calibration curve prepared using commercially available mushroom-derived tyrosinase as a standard, and was expressed as a relative value to the control. The results are shown in Table 1.
[0015]
(2) Method for measuring the number of cells (MTT activity) In the same manner as the method for measuring intracellular tyrosinase activity, the medium was removed 48 hours after acting various test specimens, and 0.05% MTT: 3- (3- The medium was replaced with 0.3 ml of MCDB153 + 5% FBS + 4 nM PMA containing 4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H-tetrazolium, and further cultured at 37 ° C. for 4 hours. 0.3 ml of isopropyl alcohol containing 0.04 NHCI was added to dissolve insoluble matters, and the absorbance at 540 nm was measured using 655 nm as a reference. The number of cells was calculated from a previously prepared calibration curve of the number of cells and absorbance and expressed as a relative value to the control. The results are shown in Table 1.
[0016]
[Table 1]
In addition, intracellular tyrosinase activity and MTT activity were measured in the same manner as described above using arbutin, which is a typical whitening agent, as a comparative example. The results are shown in Table 2.
[0018]
[Table 2]
Table 1 shows that mifepristone slightly affects the increase in the number of cells due to forskolin and α-MSH, but has a much larger effect on the increase in intracellular tyrosinase activity.
Moreover, the comparison with the arbutin shown in Table 2 shows that the action of lowering the intracellular tyrosinase activity of mifepristone is stronger than that of arbutin already used as a whitening agent at a concentration of 200 mM. Therefore, mifepristone has an excellent melanin production inhibitory effect.
[0020]
The whitening skin external preparation of the present invention may contain a substance that reduces the amount of enzyme tyrosinase in melanocytes as an essential component. In particular, it preferably contains mifepristone.
The amount is preferably 0.005 to 2% by weight of the active ingredient. If it is less than 0.005% by weight, there is no whitening effect, and if it exceeds 2% by weight, no improvement in whitening effect can be expected.
[0021]
In addition to substances that reduce the amount of enzyme tyrosinase, other cosmetic ingredients such as whitening agents such as kojic acid, ascorbic acid, hydroquinone, thiol compounds, liquid oils such as squalane and jojoba oil, beeswax, cetyl alcohol, etc. Addition of solid oil, various active agents, humectants such as glycerin and 1,3-butylene glycol, and various agents can be used to prepare skin external preparations for whitening in various dosage forms. For example, it can be used in a usage form according to the purpose, such as lotion, cream, milky lotion, and pack.
[0022]
【Example】
Example 1
An example of a lotion will be described. The blending components and blending amount (% by weight) are shown below.
Olive oil 0.5
Mifepristone 0.5
Polyoxyethylene (20 E.0) sorbitan monostearate 2.0
Polyoxyethylene (60 E.0) hydrogenated castor oil 2.0
Ethanol 10.0
Sodium hyaluronate aqueous solution (1.0 wt%) 5.0
Purified water 80.0
[0023]
Add to purified water and sodium hyaluronate solution and heat to 70 ° C. Add olive oil to polyoxyethylene (20 E.0) sorbitan monostearate and polyoxyethylene (60 E.0) hydrogenated castor oil and heat to 70 ° C. The oil phase is pre-emulsified in addition to the previously prepared aqueous phase, and further mifepristone and ethanol are added to make the emulsified particles uniform with a homomixer, followed by deaeration, filtration and cooling to obtain the lotion of Example 1. Got.
[0024]
Example 2 An example of the cream will be described. The blending components and blending amount (% by weight) are shown below.
A component:
Squalane 20.0
Olive oil 2.0
Mink oil 1.0
Jojoba oil 5.0
Beeswax 5.0
Cetostearyl alcohol 2.0
Glycerol monostearate 1.0
Sorbitan monostearate 2.0
B component:
Purified water 47.9
1. Polyoxyethylene (20 E.0) sorbitan monostearate O
Polyoxyethylene (60 E.0) hydrogenated castor oil 1.0
Glycerin 5.0
Mifepristone 0.5
Sodium hyaluronate aqueous solution (1.0 wt%) 5.0
Methyl paraoxybenzoate 0.1
[0025]
A component and B component are weighed, each is heated to 70 ° C, A component is gradually added to B component with stirring, and then cooled to 30 ° C with slow stirring to give the cream of Example 2 Obtained.
[0026]
As a result of the use test, the cosmetics obtained in Example 1 and Example 2 showed a whitening effect as compared with the comparative example in which water was replaced except for mifepristone.
[0027]
【The invention's effect】
Since this invention contains the substance which reduces the amount of enzyme tyrosinase in a melanocyte, it can suppress melanin production.
In addition, since the substance is the steroid compound described above, and particularly mifepristone, melanin production can be further suppressed.
Since melanin production can be suppressed, a whitening skin external preparation having an excellent whitening effect can be obtained.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001351904A JP3746986B2 (en) | 2001-11-16 | 2001-11-16 | Whitening agent and skin external preparation for whitening |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001351904A JP3746986B2 (en) | 2001-11-16 | 2001-11-16 | Whitening agent and skin external preparation for whitening |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003155222A JP2003155222A (en) | 2003-05-27 |
| JP3746986B2 true JP3746986B2 (en) | 2006-02-22 |
Family
ID=19164149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001351904A Expired - Fee Related JP3746986B2 (en) | 2001-11-16 | 2001-11-16 | Whitening agent and skin external preparation for whitening |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3746986B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006106813A1 (en) * | 2005-03-31 | 2006-10-12 | Japan Science And Technology Agency | Alcohol-resistant emulsion and process for producing the same |
-
2001
- 2001-11-16 JP JP2001351904A patent/JP3746986B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003155222A (en) | 2003-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3135943B2 (en) | Whitening agent | |
| US20080033037A1 (en) | Utilisation de la silymarine et/ou de ses constituants comme agents promoteur de la pigmentation de la peau ou des cheveux | |
| JPH08175960A (en) | Wrinkle prevention cosmetics | |
| JP2002003336A (en) | Cosmetic | |
| JP4675801B2 (en) | ROR activator | |
| JPH01311011A (en) | Melanization inhibitory drug for external use | |
| JP5139694B2 (en) | Melanin production inhibitor and topical skin preparation | |
| US20190142721A1 (en) | Composition containing substance for regulating expresson of abh antigens | |
| JP3746986B2 (en) | Whitening agent and skin external preparation for whitening | |
| JP2000007546A (en) | Pigmentation inhibitor, skin cosmetic and skin external preparation using the same | |
| JPH0656641A (en) | Cosmetics | |
| CN116940332B (en) | Composition for preventing hair loss or promoting hair growth comprising piperic acid | |
| JP4390177B2 (en) | Endothelin-1 mRNA expression inhibitor and endothelin-1 production inhibitor | |
| WO2024135736A1 (en) | Aqueous composition and external preparation for skin | |
| WO2002062422A1 (en) | Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof | |
| CN116459172A (en) | Anti-glycation application of vitexin | |
| JP3113407B2 (en) | Cosmetics | |
| KR100432449B1 (en) | Composition Including Ketoconazole of External Application for Skin-whitening | |
| JPH04356416A (en) | Skin cosmetic | |
| KR100511114B1 (en) | Composition including antifungal-agents of external application for skin-whitening and external application having the same | |
| JPH10226642A (en) | Therapeutic agent for skin multiplication disease | |
| JPH0940531A (en) | Hair tonic | |
| JPH08333232A (en) | Whitening agent | |
| JP2002284625A (en) | Cosmetics | |
| JP2000072650A (en) | Agent for external use for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041019 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050426 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050622 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051125 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111202 Year of fee payment: 6 |
|
| LAPS | Cancellation because of no payment of annual fees |